Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.

J Immunother Cancer · 2016 · PMC5109671 · PMID 27891225

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

In an analogous fashion, HLA-A24 + patients with high preexisting immunity had a strong trend for longer mPFS compared to those with low levels (Fig. 2d ).

also in 3,343 other papers

a weak trendno p-value reported

HLA-A2 + patients with high preexisting immunity had statistically significant longer mPFS than allele carriers with low ( p = 0.0191), whereas a weak trend for improved PFS was observed between the HLA-A2 + and HLA-A2 − patients with high preexisting immunity.

also in 834 other papers

showed a trendno p-value reported

However, HLA-A2 + patients with high preexisting or vaccine-induced immunity to E75, showed a trend for shorter PFS.

also in 33,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.